Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track SNDX with free AI briefings, catalyst countdowns, and dilution alerts.

SNDX · Syndax Pharmaceuticals Inc

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$575.1M Cash on Hand

42.8mo Cash Runway

23.5% Short Interest

$37.55 Analyst Target (11)

Follow SNDX by email Get an email when SNDX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about SNDX, unsubscribe in one click. Privacy

📣 What SNDX Says Is Next

fourth quarter of 2026 · Revumenib: “The Company expects to publish safety and efficacy data from R/R NUP98r acute leukemia patients treated with revumenib in the fourth quarter of 2026.”
Company press release, Aug 4, 2026 · SEC filing
second half of 2026 · “The Company expects the RAVEN trial to initiate in the second half of 2026.”
Company press release, Aug 4, 2026 · SEC filing
fourth quarter · Niktimvo: “We also have multiple near-term catalysts with Niktimvo Phase 2 data in IPF and frontline cGVHD expected in the fourth quarter, plus additional practice-informing and potentially guideline-enabling Revuforj data in acute leukemia.” Recent Business Highlights and Anticipated Milestones Revuforj ® (revumenib)”
Company press release, Aug 4, 2026 · SEC filing

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

🧪 Trial & FDA Catalysts

Feb 2027 · Phase 1 · Active Trial · A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute
Registry primary completion date, not a results date
Dec 2027 · Phase 1/2 · Recruiting · A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement
Registry primary completion date, not a results date
Jun 2029 · Phase 3 · Recruiting · Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Mye
Registry primary completion date, not a results date
Sep 2026 · Phase 2 · Active Trial · MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (
Registry date passed, readout not confirmed

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
Revumenib (SNDX-5613) FDA approved Nov 2024 · Revuforj	Acute Myeloid Leukemias	Phase 3 · NCT07211958	Recruiting
Gilteritinib	Previously Untreated Relapsed Refractory Acute Mye	Phase 2/3 · NCT03013998	Recruiting
Daunorubicin	Previously Untreated Relapsed Refractory Acute Mye	Phase 2/3 · NCT03013998	Recruiting
Daunorubicin or Idarubicin (BAML-16-001-	Previously Untreated Relapsed Refractory Acute Mye	Phase 2/3 · NCT03013998	Recruiting
Ivosidenib (AG-120)	Previously Untreated Relapsed Refractory Acute Mye	Phase 2/3 · NCT03013998	Recruiting
Entospletinib	Previously Untreated Relapsed Refractory Acute Mye	Phase 2/3 · NCT03013998	Recruiting
Ficlatuzumab	Previously Untreated Relapsed Refractory Acute Mye	Phase 2/3 · NCT03013998	Recruiting
Intensive Chemotherapy Regimen	Acute Myeloid Leukemias	Phase 3 · NCT07211958	Recruiting
Pevonedistat	Previously Untreated Relapsed Refractory Acute Mye	Phase 2/3 · NCT03013998	Recruiting
Samalizumab	Previously Untreated Relapsed Refractory Acute Mye	Phase 2/3 · NCT03013998	Recruiting
Dubermatinib (TP-0903)	Previously Untreated Relapsed Refractory Acute Mye	Phase 2/3 · NCT03013998	Recruiting
Lomonitinib	Previously Untreated Relapsed Refractory Acute Mye	Phase 2/3 · NCT03013998	Recruiting
Enasidenib (AG-221)	Previously Untreated Relapsed Refractory Acute Mye	Phase 2/3 · NCT03013998	Recruiting
Bivalent BRD4 Inhibitor AZD5153	Previously Untreated Relapsed Refractory Acute Mye	Phase 2/3 · NCT03013998	Recruiting
Mcl-1 Inhibitor AZD5991	Previously Untreated Relapsed Refractory Acute Mye	Phase 2/3 · NCT03013998	Recruiting
Anti-CD33 Monoclonal Antibody BI 836858	Previously Untreated Relapsed Refractory Acute Mye	Phase 2/3 · NCT03013998	Recruiting

Also used in these trials (approved or third-party drugs, not SNDX's own candidates): Cytarabine, Decitabine, Venetoclax, Azacitidine, Avelumab, Momelotinib, Nivolumab, Pembrolizumab, Cobicistat, Anastrozole, Atezolizumab, Ruxolitinib.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

SNDX holds $575.1M in cash and short-term investments (as of Jun 30, 2026) and burns about $40.3M/quarter from operations, an estimated runway of 42.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 25 · Moderate

Cash runway 43 months
ATM program on file since Feb 2024 +15
Shelf registration (S-3ASR, Feb 2024) +10

Recent financing filings on SEC EDGAR:

Jun 10, 2026 · Private placement (8-K Item 3.02) · 8-K
Jun 4, 2026 · Private placement (8-K Item 3.02) · 8-K
Feb 27, 2024 · Shelf registration with ATM program, up to $157M · S-3ASR
Dec 15, 2023 · Underwritten offering, $200M · 424B5
Dec 14, 2023 · Underwritten offering · 424B5

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SNDX files for a raise →

👥 Who Owns SNDX

Insiders 1.8% Institutions (343 holders) 98.2% Public and other holders 0%

Holder	Type	Shares	% of shares	As of
Blackrock Inc.	Institution (13F)	9,020,006	10.10%	2026-06-30
Kynam Capital Management, LP	Institution (13F)	8,050,959	9.02%	2026-06-30
Goldman Sachs Group Inc	Institution (13F)	5,861,265	6.56%	2026-06-30
STATE STREET CORPORATION	Institution (13G, 5%+)	5,658,465	6.34%	2026-06-30
Vanguard Capital Management	Institution (13G, 5%+)	4,457,143	4.99%	2026-03-31
Bank of America Corporation	Institution (13F)	4,045,094	4.53%	2026-06-30
Deerfield Management Company, L.P	Institution (13F)	3,779,900	4.23%	2026-06-30
Eversept Partners, LP	Institution (13F)	2,798,210	3.13%	2026-06-30
Geode Capital Management, LLC	Institution (13F)	2,584,136	2.89%	2026-06-30
Hood River Capital Management LLC	Institution (13F)	2,564,279	2.87%	2026-06-30
Michael A Metzger Chief Executive Officer, Director · +804,000 options	Insider	484,843	0.54%	2026-07-08
Dennis Podlesak Director	Insider	239,763	0.27%	2026-02-04

Share count 89,297,086 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade date	Insider	Transaction	Shares	Price	Owned after
2026-07-08 filed 2026-07-09	Metzger Michael A	Sale (S)	32,375	$24.24	484,843
2026-07-08 filed 2026-07-09	Metzger Michael A	Option exercise (M)	32,375	$6.38	517,218
2026-07-08 filed 2026-07-09	Metzger Michael A	Option exercise (M)	32,375	–	–
2026-06-12 filed 2026-06-12	Botwood Nicholas A.J.	Option exercise (M)	31,235	–	–
2026-06-12 filed 2026-06-12	Botwood Nicholas A.J.	Sale (S)	31,235	$18.14	60,885

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

📅 Past FDA Decisions & Stock Reactions

Date	Drug	Type	Run-up 30d	Decision 1d	After 5d
2025-10-25	Revuforj	sNDA	-10%	-3.1%	+1.3%

Browse all historical PDUFA outcomes →

Get the full SNDX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SNDX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z